Expertise in
10
conditions

Dr. Avi B. Markowitz

Internal Medicine
Office
1005 Harborside Dr, 
Galveston, TX 
Accepting New Patients
Expertise in
10
conditions
Office
1005 Harborside Dr, 
Galveston, TX 

Overview

Avi Markowitz is a primary care provider, practicing in Internal Medicine in Galveston, Texas.

Dr. Markowitz is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Familial Colorectal Cancer, Breast Cancer, Breast Cancer in Men, and Gastrointestinal Stromal Tumor.

He is actively involved in clinical research, co-authoring 7 peer reviewed articles and participating in 7 clinical trials. Dr. Markowitz is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in TX

Hospital Affiliations

University Of Texas Medical Branch Galveston

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Office
1005 Harborside Dr, Galveston, TX 77550

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
A Phase 1b Study of Berzosertib in Combination With Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
A Phase 1b Study of Berzosertib in Combination With Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Radiation, Drug, Procedure
Study Drug: Berzosertib
Study Phase: Phase 1
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2026
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Completed
Publish Date: April 08, 2026
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Veliparib
Study Phase: Phase 2
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination With Fulvestrant in Patients With Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor
A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination With Fulvestrant in Patients With Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor
Enrollment Status: Withdrawn
Publish Date: September 25, 2023
Intervention Type: Drug
Study Drugs: Copanlisib, Fulvestrant
Study Phase: Phase 1/Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
View 6 Less Clinical Trials

7 Total Publications

Non-neoplastic inflammatory pseudotumor of the lung after immunotherapy for melanoma: A diagnostic pitfall on fine needle aspiration biopsy of lung.
Non-neoplastic inflammatory pseudotumor of the lung after immunotherapy for melanoma: A diagnostic pitfall on fine needle aspiration biopsy of lung.
Journal: Diagnostic cytopathology
Published: April 08, 2021
Similar Doctors
Expertise in
26
conditions
Dr. Michael L. Eisenberg
Internal Medicine
Expertise in
26
conditions
Dr. Michael L. Eisenberg
Internal Medicine

Office

711 W Bay Area Blvd Ste 602, 
Webster, TX 
 (26.6 miles away)
832-871-4099
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Eisenberg is a primary care provider, practicing in Internal Medicine in Webster, Texas. Dr. Eisenberg is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Infertility, Peyronie Disease, Erectile Dysfunction (ED), Gastrostomy, and Hormone Replacement Therapy (HRT). Dr. Eisenberg is currently accepting new patients.

Expertise in
17
conditions
Dr. Preetesh M. Jain
Internal Medicine
Expertise in
17
conditions
Dr. Preetesh M. Jain
Internal Medicine

UT MD Anderson Cancer Center

1515 Holcombe Blvd, 
Houston, TX 
 (46.1 miles away)
713-792-1101
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Preetesh Jain is a primary care provider, practicing in Internal Medicine in Houston, Texas. Dr. Jain is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, Leukemia, Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration.

Expertise in
26
conditions
Dr. Maro N. Ohanian
Internal Medicine
Expertise in
26
conditions
Dr. Maro N. Ohanian
Internal Medicine

University Of Texas MD Anderson Cancer Center

1515 Holcombe Blvd Unit 428, 
Houston, TX 
 (46.4 miles away)
713-792-8760
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Maro Ohanian is a primary care provider, practicing in Internal Medicine in Houston, Texas. Dr. Ohanian is highly rated in 26 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Avi B. Markowitz

How do I make an appointment with Dr. Avi B. Markowitz?

You can book an appointment with Dr. Avi B. Markowitz by calling their office at 832-505-1910. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Avi B. Markowitz a top-rated expert for Familial Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Avi B. Markowitz is classified as an Advanced expert for Familial Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Avi B. Markowitz specialize in?

While Dr. Avi B. Markowitz is a Internal Medicine, they have specific expertise in Familial Colorectal Cancer, Breast Cancer, and Breast Cancer in Men. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Avi B. Markowitz participate in research or clinical trials?

Yes. Dr. Avi B. Markowitz has published 7 articles and abstracts on conditions like Familial Colorectal Cancer. You can view a list of Dr. Avi B. Markowitz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Avi B. Markowitz accept my insurance?

Dr. Avi B. Markowitz accepts most major insurance plans, including Cigna and Community Health. We recommend calling the office directly at 832-505-1910 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Markowitz's expertise for a condition
ConditionClose
      View All 10 Advanced Conditions
      View All 75 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile